Ascelia Pharma

Declaration of Voting Results & Voting Rights Announcements • Sep 30, 2024

PRESS RELEASE

30 September 2024 15:25:00 CEST

Change in Number of Shares and Votes in Ascelia Pharma AB

During September, the registered number of shares and votes in Ascelia Pharma AB ("Ascelia Pharma") has increased due to the rights issue of units resolved by the Board of Directors on 10 July 2024 and approved by the Extraordinary General Meeting on 14 August 2024. As of 30 September 2024, the total number of shares in Ascelia Pharma amounts to 97,193,153 shares, whereof 96,079,722 are ordinary shares with one vote each and 1,113,431 are series C shares with 1/10 vote each. The total number of votes as of 30 September 2024 amounts to 96,191,065.1.

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

Contacts

Magnus Corfitzen, CEO Email: moc@ascelia.com Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)

Email: jwb@ascelia.com Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

This information is information that Ascelia Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-09-30 15:25 CEST.

Attachments

Change in Number of Shares and Votes in Ascelia Pharma AB